A patient in the lab
HUB Organoids™ predict patient response to treatment.
Our technology allows the development of patient-derived “mini-organs in a dish” from both healthy and diseased tissues to close the gap between the lab and the clinic.
find out moreWhat can we do for you?
Commercial use
means use of the HUB Organoid Technology and HUB Organoids™ by any user that is a commercial entity, or an entity engaged in commercial activities in respect of the use of HUB Organoid Technology and HUB Organoids, for commercial purposes including, without limitation:
- to provide a service to a person or entity in return for a transfer of value (whether in cash or in kind);
- to research, screen, test or develop products for in-house purposes or for third parties;
- for resale purposes;
- to produce, propagate or otherwise manufacture organoids or organoid media for general sale;
- use in the manufacturing of other products;
- for or in connection with proficiency testing services including, but not limited to, providing services on or in relation to laboratory performance by comparing and evaluating calibrations or tests on the same or similar items or materials in accordance with predetermined conditions;
- for consumption by, or administration and/or application to, humans or animals;
- for research sponsored or undertaken by or on behalf of: (i) a commercial entity or organization (other than Purchaser); (ii) any other legal entity in the context of commercial activities; or (iii) a public/private partnership; or
- for any other financial gain (whether in cash or in kind) excluding research grants.
Academic use
means use of HUB Organoid Technology and HUB Organoids for research and educational purposes provided that any sort of commercial purposes are not involved.
Latest news
September 10, 2021
6th PREDiCT 3D Tissue Models
Meet our speaker Dr. Sylvia Boj discussing the next-gen models for…
read more
September 2, 2021
New PERSIST-SEQ program launched
2 September 2021, Utrecht (The Netherlands) - Hubrecht Organoid Technology (HUB) joins a new international…
read more
September 1, 2021
2021 Organoids are us
New online presentation available on the use of HUB Organoids™ as a revolutionary approach to disease modeling, drug screening,…
read more
August 31, 2021
Link revealed between HBV infection and liver cancer
HUB Organoids derived from patients with chronic hepatitis B show the first molecular signs of liver cancer.
read more
August 18, 2021
New service partnership
VANCOUVER, British Columbia - STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that…
read more
August 12, 2021
CF models for drug development
HUB Organoids™ supports the on-going clinical evaluation of ELX-02 as a therapeutic agent for cystic fibrosis (CF)
read more
August 5, 2021
Test epithelial barrier function
Discover the development of a new model to assess drug safety, absorption, methabolism, transport, and permeability.
read more
July 28, 2021
Model human diseases and select treatment
Our CEO Dr. Rob Vries discusses how HUB Organoids help modelling human disease and select best treatement options
read more
July 27, 2021
Model inflammation in a dish
Watch Dr. Sylvia Boj discussing how HUB Organoids accelerate the development of new therapeutics for inflammatory diseases.
read more
July 14, 2021
HUB at Innovation Parade
HUB takes centre stage during this year’s Olympic games in Tokyo by sponsoring the …
read more
April 26, 2021
HUB and Yamaha for IVD
April 26, 2021 - Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd.…
read more
September 4, 2020
Next-gen diagnostics
Utrecht and Qingdao, Sep 4th, 2020 – Hubrecht Organoid Technology (HUB) and BGI-Qingdao announced…
read more
July 20, 2020
Organoids for infectious disease
During this virtual mini-symposium co-hosted with our partner STEMCELL Technologies we discuss the development and…
read more
May 27, 2020
Ovarian cancer organoids
Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade…
read more
May 13, 2020
Understanding gut’s hormones
Hormone-producing cells in the human gut are difficult to study, as they are very rare and unique to different species of…
read more
May 1, 2020
SARS-CoV-2 infects gut cells
Researchers from the Hubrecht Institute in Utrecht, Erasmus MC University Medical Center Rotterdam, and Maastricht University in…
read more
April 1, 2020
A message from our CEO
Dear Valued Customer,
On Wednesday 11th March the World Health Organization (WHO) declared a pandemic in response to…
read more
February 20, 2020
Organoids for genetic disorders
Whereas the CRISPR/Cas9 technology cuts out a defect in a gene and replaces it with a new piece, the latest CRISPR technology…
read more
December 10, 2019
HUB on Financial Times
On December 10, 2019 the Financial Times featured HUB Organoids™ in …
read more
October 17, 2019
PDX organoids in drug development
San Diego, October 17, 2019 – Crown Bioscience today announced the launch of a new tumor organoid drug development platform…
read more
October 1, 2019
Organoids-on-a-chip
Leiden, Utrecht September 2019 - MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into…
read more
July 16, 2019
Epistem license HUB Technology
Manchester, 16th July, 2019 - Epistem Limited, the UK based pre-clinical and clinical research services company…
read more
May 19, 2019
HUB PDOs now at CrownBio
San Diego, Calif – May 19, 2020 — Crown Bioscience today announced the expansion of their unique organoid…
read more
February 1, 2019
New partner: Yamaha Motor
February 1, 2019 – Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd. (Tokyo:7272) announced today their…
read moreWant to know more?
Please contact us at +31 (0)88 12 36 300 or email us info@huborganoids.nl or drop us a message via the button below.
contact us